Abstract
The purpose of these studies was to achieve desired bioavailability after pulmonary administration of Levonorgestrel (LN) and to provide prolonged effective concentration of the drug in plasma and to reduce reported side effects of orally administered drug. The plain drug suspension, physical mixture (plain drug with liposomal constituents), and drug-encapsulated liposomes containing 10 μg of drug were instilled intratracheally in rats. Similarly, 10-μg drug suspension (LO) was administered orally. The blood samples were withdrawn at specific time intervals and were subjected to LN analysis by spectrofluorimetric technique. The plasma drug concentration data of both the treatments were plotted, and pharmacokinetics data were calculated and compared with that of oral administration. Percentage relative bioavailability (F*) of 97.6% 98.6%, and 109.9% were observed after pulmonary administration of plain drug formulation (LP1), physical mixture (plain drug along with constituents of liposomes [LP2], and liposomal (LP3) formulations of the drug, respectively. Following oral administration, Cmax of 14.4±0.6 ng/mL was observed at 2.1±0.2 hours followed by subtherapeutic concentration beyond 30±0.2 hours, while after pulmonary administration of LP1, LP2, and LP3 formulations, Cmax of 4.4±0.4 ng/mL, 4.2±0.5 ng/mL, and 4.4±0.6 ng/ML were observed at 6.0±0.2 hours, 7.0±0.2 hours, and 6.8±0.2 hours, respectively, followed by maintenance of effective plasma drug concentration up to 60±2 hours. These studies demonstrate superiority of pulmonary drug delivery with regards to maintenance of effective therapeutic concentration of the LN in the plasma over a period of 6 to 60 hours. Hence, the pulmonary delivery is expected to reduce frequency of dosing and systemic side effects associated with oral administration of LN.
Similar content being viewed by others
References
Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens.N Engl J Med. 2002;346:340–352.
Mueck AO, Seeger H, Graser T, Oettel M, Lippert TH. The effects of postmenopausal hormone replacement therapy and oral contraceptives on the endogenous estradiol metabolism.Horm Metab Res. 2001;33:744–747.
Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, Hollenberg PF. Effect of 17-alphaethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites.J Pharmacol Exp Ther. 2002;300:549–558.
Ellison J, Thomson AJ, Greer IA, Walker ID. Drug points: apparent interaction between warfarin and levonorgestrel used for emergency contraception.BMJ. 2000;1321–1382.
Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.Lancet. 1999;354:2036–2040.
McCann MF, Potter LS. Progestin-only oral contraception: A compre-hensive review.Contraception. 1994;50(6 suppl 1): S1–195.
Vyas SP, Khar RK.Nasopulmonary Drug Delivery in Controlled Drug Delivery: Concept and Advances. Vallabh Prakashan, India: 2002;341–342.
Shek PN, Barber RF. Liposomes: a new generation of drug and vaccine carriers.Mol. Med. Canada. 1986;41:314–326.
Kimelberg HK, Mayhew EG. Properties and biological effects of liposomes and their uses in phamacology and toxicology.CRC Crit Rev Toxicol. 1978;6(1):25–79.
Szoka F, Papahadjopoulos D. Liposomes: preparation and characterization. In: Knight CG, ed.Liposomes: From Physical Structure to Therapeutic Applications. New York, NY: Elsevier/North-Holland Biomedical Press, 1981:51–82.
Poznansky MJ, Juliano RL. Biological approaches to the controlled delivery of drugs: A critical review.Pharmacol Rev. 1984;36:277–336.
Knight CG.Liposomes: From Physical Structure to Therapeutic Application. New York, NY: Elsevier/North-Holland Biomedical Press, 1981.
Joshi MR, Misra AN. Dry powder inhalation of liposomal ketotifen fumarate: Formulation and characterization.Int J Pharm. 2001b;223:15–27.
Enna SJ, Schanker LS. Absorption of drugs from the rat lung.Am J Physiol. 1972;223:1127–1231.
Andrew SM, Leo CF. Norgestrel. In: Florey K, ed.Analytical Profile of Drug Substances. Vol. 4 New York NY: Academic Press; 1975.
Gibaldi M, Perri D.Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker, 1982.
Anderson MW, Orton TC, Pickett RD, Eling TE. Accumulation of amines in the isolated perfused rabbit lung.J Pharmacol Exp Ther. 1974;189:456–466.
Suhara T, Sudo Y, Yoshida K, et al. Lung as reservoir for antidepressants in pharmacokinetics drug interactions.Lancet. 1998;351:332–335.
Roerig DL, Kotrly KJ, Dawson CA, Ahlf SB, Gualtieri JF, Kampine JP. First-pass uptake of verapamil, diazepam, and thiopental in the human lung.Anesth Analg. 1989;69:451–466.
Jorfeldt L, Lewis DH, Lofstrom JB, Post C. Lung uptake of lidocaine in healthy volunteers.Acta Anaesthesiol Scand. 1979;23:567–574.
Dollery CT, Junod AF. Concentration of (±)-propranolol in isolated, perfused lungs of rat.Br J Pharmacol. 1976;57:67–71.
Juliano RL, McCullogh HN. Controlled delivery of an anti tumor drug: Localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system.J Pharmacol Exp Ther. 1980;214:381–388.
Shek PN, Jurima-Romet M. Lung uptake of liposome-entraped glutathione after intratracheal administration.J Pharm Pharmacol. 1991;43:6–10.
Juliano RL, McCullogh HN. Controlled delivery of an anti tumor drug: Localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system.J Pharmacol Exp Ther. 1980,214:381–388.
Brown RA, Schanker LS. Absorption of aerosolized drugs from the rat lung.Drug Metab Dipos. 1983;11:355–360.
Schanker LS, Mitchell EW, Brown RA, Jr. Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection.Drug Metab Dispos. 1986;14:79–88.
Brain JD, Knudson DE, Sorokin SP, Davis MA. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation.Environ Res. 1976;11:13–33.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shahiwala, A., Misra, A. Pulmonary absorption of liposomal levonorgestrel. AAPS PharmSciTech 5, 13 (2004). https://doi.org/10.1208/pt050113
Received:
Accepted:
Published:
DOI: https://doi.org/10.1208/pt050113